Gilead halts blood cancer drug tests as trial patients die
March 15, 2016 at 16:00 PM EDT
Gilead Sciences Inc. has shut down six clinical trials with its blood cancer drug Zydelig after an increase in adverse events, including deaths, casting doubts on whether the drug will move from a followup treatment to the front line...